On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdaySep 22, 2016 3:21 pm

GSK (GSK) Shingles Vaccine Phase III Study Shows High Efficacy in Adults Aged 70 and Over

An investigational shingles vaccine developed by global pharmaceutical and healthcare company GlaxoSmithKline (NYSE: GSK) is showing high efficacy against the ailment and various complications in adults over 70, according to a press release issued by the company on Wednesday, September 14. The findings are included in the results of a randomized phase III study (ZOE-70) of the Shingrix™ vaccine, published in the New England Journal of Medicine. The ZOE-70 study, conducted on more than 14,800 subjects in North America, Latin America, Europe and Asia-Pacific, shows that the candidate shingles vaccine, administered in two doses, has an efficacy rate of 90%…

Continue Reading

ThursdaySep 22, 2016 2:44 pm

Function(x) Inc. (FNCX) Begins Trading on Split-Adjusted Basis

Function(x) Inc. (NASDAQ: FNCX) recently announced that it has started trading on a reverse split-adjusted basis as of the opening of the market on Friday, September 16, 2016. The company’s common stock shares will be traded at a ratio of 1-for-20 shares. The reverse stock split was approved by Function(x)’s board of directors the previous week in order for the company to recover and stay within the lowest closing bid price of $1.00 per share to maintain its NASDAQ status. Function(x) will continue to trade under the same ticker symbol of FNCX. As a result, every 20 pre-split outstanding shares…

Continue Reading

ThursdaySep 22, 2016 11:29 am

Horizon Pharma plc (HZNP) is “One to Watch”

Headquartered in Dublin, Ireland, Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company whose aim is to improve lives with the recognition, development, acquisition, and commercialization of accessible medicines to meet a variety of patient medical needs. Horizon Pharma now markets nine key products through its orphan, rheumatology, and primary care business units. Products include ACTIMMUNE®, Buphenyl®, Duexis®, KRYSTEXXA®, Migergot®, PENNSAID® 2%, Ravicti®, Rayos®, and Vimovo®. These products are used to reduce the frequency and severity of serious infections, treat patients with urea cycle disorders, relieve signs and symptoms of rheumatoid arthritis and osteoarthritis, decrease the risk of developing upper gastrointestinal…

Continue Reading

ThursdaySep 22, 2016 9:09 am

iGambit, Inc. (IGMB) Leaning on Seasoned Leadership Team to Guide Acquisition-Based Growth Model

iGambit, Inc. (OTCQB: IGMB) is a diversified holding company focused primarily on the acquisition of early-stage technology firms with strong growth potential that’s easily recognized in the public arena. Leveraging the considerable industry experience of its board of directors and management team, iGambit offers talented entrepreneurs an opportunity to focus their time and energy on building a business instead of searching out investors or raising capital. Following acquisition, iGambit provides the capital and management expertise required to help its partner firms flourish with the intention of ‘spinning off’ the acquisition to the benefit of both the newly independent business and…

Continue Reading

WednesdaySep 21, 2016 3:50 pm

SITO Mobile (SITO) Announces Pricing of $10 Million Underwritten Public Offering

Leading mobile engagement platform SITO Mobile Ltd. (NASDAQ: SITO) on Friday, September 16, announced a $10 million underwritten public offering. The offering is expected to close on Tuesday, September 21. The underwritten public offering consists of 2,666,667 shares of common stock at an offering price of $3.75 each. SITO Mobile also made available a 30-day option that would allow underwriters to purchase up to 400,000 additional shares at the same price. The decision is designed to cover overallotments that result from the underwritten public offering. The New Jersey company expects gross proceeds of $10 million and approximately $9.3 million after…

Continue Reading

WednesdaySep 21, 2016 3:32 pm

MabVax (MBVX) Tackling Cancer with Diagnostics and Therapeutics

Recently, David Hansen, the CEO of MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), spoke to Jane King of Small Cap Nation about current developments at the clinical-stage biotechnology company. They were joined by Jeffrey Kraws, founder and senior analyst at Crystal Research Associates. MabVax is an oncology drug development company with a number of technologies to discover antibodies from patient immune responses against their cancers. The antibodies so derived from humans are then used to develop products for the diagnosis and treatment of metastatic solid tumor cancers. Human-derived antibodies have less chance of being rejected by the body, as CEO David…

Continue Reading

WednesdaySep 21, 2016 12:14 pm

Pay-by-Text™ from Singlepoint, Inc. (SING) Makes Mobile Payments as Easy as SMS

A recent feature in Fortune magazine titled ‘How mobile payments will grow in 2016’ (http://nnw.fm/DrEs0) shows the rosy future that lies before Singlepoint, Inc. (OTC: SING). The Fortune piece reports that ‘eMarketer (is) forecasting 210% growth in the total value of mobile payment transactions in 2016—up to $27.05 billion from $8.71 billion’. This is a market that is still in its infancy, and Singlepoint’s Pay-by-Text™ technology is precisely the sort of cutting edge innovation that can establish a niche in it. Despite the promise of easier use and convenience, the Fortune piece reveals that ‘while 52% of North Americans are…

Continue Reading

WednesdaySep 21, 2016 9:06 am

eXp World Holdings, Inc. (EXPI) Taking the Complexity Out of Real Estate Transactions

eXp World Holdings, Inc. (OTCQB: EXPI) serves as the holding company for multiple companies, including eXp Realty. Through eXp Realty, the corporation is using innovation to better develop real estate prospects and is effectively changing how real estate dealings are conducted. Recent strides in the tech and e-commerce fields have had a substantial effect on how numerous industries (real estate included) operate. Buyers and sellers have more on-the-spot data at their fingertips via the Internet, yet the home buying and selling process remains a complex and often emotional activity. This is where eXp Realty comes in, as a tried-and-tested organization…

Continue Reading

TuesdaySep 20, 2016 3:22 pm

Range Resources (RRC) and Memorial Resource Development Corp. Close Merger Agreement

On September 16, 2016, Range Resources Corporation (NYSE: RRC) entered into a merger agreement with Memorial Resource Development Corp. (NASDAQ: MRD), as previously agreed upon by shareholders of both companies. Under the agreement, RRC receives all of MRD’s remaining shares of common stock in an all-stock arrangement. The arrangement is worth over $4 billion and incorporates MRD’s net debt. In a news release, Jeff Ventura, CEO of Range Resources Corporation, stated, “We are excited to announce the closing of the Memorial transaction and believe this is a significant milestone for Range. We welcome the newest members of the Range team…

Continue Reading

TuesdaySep 20, 2016 3:03 pm

Mattress Firm Holding Corp. (MFRM) Acquired by Steinhoff International Holdings N.V.

Mattress Firm Holding Corp. (NASDAQ: MFRM), the nation’s largest mattress retailer, recently announced the completion of its acquisition by South Africa-based Steinhoff International Holdings N.V. Steinhoff paid $64 per share in cash for Mattress Firm, which represented a premium of 115 percent over the company’s closing stock price of $29.75 on August 5, 2016. The acquisition became effective on September 16. Moving forward, Mattress Firm will operate as a subsidiary of Steinhoff. The mattress retailer’s existing management team, led by Steve Stagner, the company’s executive chairman, and Ken Murphy, president and CEO, will remain in place in order to run…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217